Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY:BMY)

46.92 -0.09 (-0.19%)
Official Closing Price Updated: 5:00 PM EDT, Jul 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
75 76 Next >
Bristol Myers Squibb Completes Acquisition of Karuna Therapeutics, Strengthening Neuroscience Portfolio
From Bristol Myers Squibb
Via Business Wire
FDA Advisory Committee Votes in Favor of Bristol Myers Squibb’s and 2seventy bio’s Abecma for Triple-Class Exposed Multiple Myeloma in Earlier Lines of Therapy
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' Breyanzi Scores Second FDA Approval For Blood Cancers Therapy
FDA grants accelerated approval to Bristol Myers Squibb's Breyanzi, a CAR T cell therapy for relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma after two prior lines of... 
Via Benzinga
Why NYSE:BMY is a Top Pick for Dividend Investors.
Is BRISTOL-MYERS SQUIBB CO (NYSE:BMY) a Good Fit for Dividend Investing? 
Via Chartmill
Unpacking the Latest Options Trading Trends in Bristol-Myers Squibb
Via Benzinga
Bristol-Myers Squibb's Options Frenzy: What You Need to Know
Via Benzinga
What's Going On With Cancer Focused-Geron Stock On Friday?
Geron sees lower share price with high volume. FDA committee votes favorably on imetelstat for transfusion-dependent anemia in adult MDS patients. June 16, 2024, set as FDA target action date.... 
Via Benzinga
U.S. FDA Approves Bristol Myers Squibb’s Breyanzi® as the First and Only CAR T Cell Therapy for Adults with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)
From Bristol Myers Squibb
Via Business Wire
FDA To Review Two Cell Therapies For Multiple Myeloma This Week - Johnson & Johnson And Bristol-Myers
Join the FDA's Oncologic Drugs Advisory Committee on March 15th to review Johnson & Johnson/Legend Biotech's Carvykti application for relapsed/refractory multiple myeloma treatment. Delve into... 
Via Benzinga
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
How Is The Market Feeling About Bristol-Myers Squibb?
Via Benzinga
Be A Smart Investor – Don’t Hold On For Dear Life
You have to give credit where it’s due. The bulls have been relentless for almost 18 months, but certainly over the past 5 months. 
Via Talk Markets
Bristol Myers Squibb to Report Results for First Quarter 2024 on April 25, 2024
From Bristol Myers Squibb
Via Business Wire
Arcellx's Lead Asset Can Potentially Outperform Bristol-Myers Squibb, Johnson & Johnson's Multiple Myeloma Cell Therapies: Morgan Stanley
Morgan Stanley initiates coverage on Arcellx. Uncover the potential of ddBCMA in blood cancer treatment, featuring a differentiated CAR-T platform. Analysts project $5 billion in peak sales. 
Via Benzinga
U.S. Food and Drug Administration Approves Opdivo® (nivolumab), in Combination with Cisplatin and Gemcitabine, for First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma
From Bristol Myers Squibb
Via Business Wire
Medicare's Ambitious Drug Price Negotiation Plan: President Joe Biden Calls To Expand Targeted Medicines To 50 Annually by 2029
Explore President Biden's plan to expand Medicare drug negotiations, targeting at least 50 drugs annually. Uncover the impact on pharmaceutical profits and the broader health-care policy proposals,... 
Via Benzinga
Bristol Myers Squibb to Participate in Upcoming Investor Conferences
From Bristol Myers Squibb
Via Business Wire
Millionaire’s Blueprint: 7 Must-Have Stocks for Your Road to Wealthy Town
Discover must-have stocks for wealth for every investor, from healthcare and communication giants to financial and industrial sectors. 
Via InvestorPlace
Biden's State Of The Union: Grading His Results On Abortion Access, Drug Prices And Opium Epidemic
As President Biden prepares for his State of the Union address, he will address issues such as Bidenomics, healthcare, and the US's role in the world. 
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Bristol Myers Squibb Announces Dividend
From Bristol Myers Squibb
Via Business Wire
The Hot List: 3 AI Stocks Worth Buying on Weakness
Firms using AI directly can be great picks for long-term investors, such as these three AI stocks to buy on weakness. 
Via InvestorPlace
Topics Artificial Intelligence
Bristol Myers Squibb Announces New Data from the Long-Term DAYBREAK Study Reinforcing Efficacy and Safety of Zeposia (ozanimod) in Patients with Relapsing Forms of Multiple Sclerosis
From Bristol Myers Squibb
Via Business Wire
Large US Drug Makers Highlight Indian Market For Their Blockbuster Drugs Including For Weight Loss
Eli Lilly's CEO, David Ricks, outlines plans to launch the obesity drug Tirzepatide in India next year, presenting opportunities amid competition from Novo Nordisk. Bristol Myers Squibb expands its R&D... 
Via Benzinga
Bristol Myers Squibb to Participate in the TD Cowen 44th Annual Health Care Conference
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform
From Bristol Myers Squibb
Via Business Wire
3 Highly Rated Biotech Stocks to Buy for 300% Gains
Biotech stocks like those discussed here have the potential to produce 300% returns and benefit from high analyst ratings. 
Via InvestorPlace
Bristol Myers Squibb Receives Positive CHMP Opinion for Reblozyl® (luspatercept) for Treatment of Adults with Transfusion-Dependent Anemia due to Low- to Intermediate-Risk Myelodysplastic Syndromes (MDS)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer
From Bristol Myers Squibb
Via Business Wire
Mental Health Mavericks: 3 Stocks Changing the Game
Except for the psychedelics movement, there seem to be very few mental health stocks to buy that are making money. 
Via InvestorPlace
< Previous 1 2
...
20 21 22 23 24 25 26 27 28
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS